Abstract
晚期肾癌预后差而且对放化疗抗拒,免疫治疗仅使极少部分患者受益.血管内皮生长因子(VEGF)在肾透明细胞癌过量表达,表明它可以作为一个新的靶向治疗途径.经过临床试验证实,以VEGF为靶向通路的药物在治疗肾癌方面取得令人鼓舞的效果。
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
